BioXcel Therapeutics Inc <BTAI.OQ> expected to post a loss of $6.38 a share - Earnings Preview
BioXcel Therapeutics Inc BTAI.OQ BTAI.O is expected to show a rise in quarterly revenue when it reports results on March 10 (estimated) for the period ending December 31 2024
The New Haven Connecticut-based company is expected to report a 87.9% increase in revenue to $706.67 thousand from $376 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for BioXcel Therapeutics Inc is for a loss of $6.38 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $32.00, above its last closing price of $2.74.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -8.00 | -8.67 | -5.12 | Beat | 40.9 |
Jun. 30 2024 | -11.12 | -11.36 | -3.36 | Beat | 70.4 |
Mar. 31 2024 | -10.25 | -11.17 | -13.92 | Missed | -24.6 |
Dec. 31 2023 | -15.12 | -14.56 | -12.16 | Beat | 16.5 |
Sep. 30 2023 | -21.50 | -20.86 | -27.52 | Missed | -31.9 |
Jun. 30 2023 | -28.83 | -28.01 | -29.28 | Missed | -4.5 |
Mar. 31 2023 | -28.96 | -25.89 | -29.44 | Missed | -13.7 |
Dec. 31 2022 | -23.92 | -23.14 | -31.20 | Missed | -34.8 |
This summary was machine generated March 7 at 12:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Investing in Specialized Real Estate
TradingKey - Niche assets like data centers, logistics, healthcare, and cold storage thrive on structural drivers, not traditional property cycles Specialized real estate benefits from secular trends like digitalization, demographics, and supply chain innovation
Oracle Q1 FY2026 Earnings: Cloud Surge and Record RPO Fuel AI Optimism
TradingKey - Oracle Corporation (NYSE: ORCL) posted mixed Q1 FY2026 results, with total revenue and adjusted EPS slightly below consensus amid a shift to cloud services, but cloud revenue beat expectations with robust 28% growth. A massive RPO backlog of $455 billion, up 359% YoY
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.
Trump presidency could deal heavy blow to Germany's flagging economy
WASHINGTON (Reuters) - Germany would be the big loser if a Trump presidency sparked a tit-for-tat trade war between the United States and Europe, with Germany's previously much-envied industrial strength potentially becoming an acute vulnerability.
